All Trials

A Phase 1 and Randomized Phase 2 Trial of Pidnarulex (CX-5461) and Cemiplimab (REGN2810) in Refractory Microsatellite Stable Colorectal Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolls adults with refractory unresectable/metastatic pMMR/non–MSI-H colorectal adenocarcinoma after standard chemotherapy/biologics; phase 2 further selects for liver metastases plus MYC amplification or deleterious FBXW7 mutation. Treatment is pidnarulex/CX-5461, an investigational G-quadruplex stabilizer that induces replication-dependent DNA damage and has been characterized as an RNA polymerase I transcription inhibitor, alone or combined with the anti–PD-1 antibody cemiplimab.

ClinicalTrials.gov ID: NCT07147231

A Phase 1/2, Dose Escalation and Expansion Trial to Evaluate the Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with refractory metastatic colorectal adenocarcinoma, ECOG 0–1, measurable disease, and documented RAS/BRAF/MSI status after standard therapies receive IV tegavivint, a first-in-class TBL1 inhibitor that disrupts β-catenin/Wnt signaling, as weekly monotherapy with dose escalation/expansion. Later cohorts evaluate tegavivint at the recommended dose in combination with unspecified standard-of-care colorectal cancer regimens.

ClinicalTrials.gov ID: NCT07463599

ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adults with locally advanced unresectable or metastatic RCC with measurable disease, including clear cell and non-clear cell RCC in phase 1 and clear cell RCC in phase 2, with most patients treatment-naive in the metastatic setting. Evaluates pumitamig/BNT327, a bispecific PD-L1 and VEGF-A antibody, alone or with ipilimumab or cabozantinib, with randomized phase 2 comparison against nivolumab-based standard regimens.

ClinicalTrials.gov ID: NCT07293351

A Multicenter, Open-label, Phase 3 Extension Study to Evaluate the Long-term Efficacy and Safety in Participants Who Are Currently on Treatment in a Belzutifan Study (LITESPARK-043)

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

TrialFetch AI summary: Open-label extension for clinically stable patients with advanced solid tumors or VHL disease–related neoplasms who are already receiving therapy in an eligible belzutifan parent study. Participants continue their prior regimen: belzutifan (oral HIF-2α inhibitor) alone or with agents such as palbociclib, nivolumab, lenvatinib, or cabozantinib, or comparator therapy such as lenvatinib, cabozantinib, or everolimus.

ClinicalTrials.gov ID: NCT07405164

AN INTERVENTIONAL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with treatment-naïve locally advanced unresectable or metastatic RCC, ECOG 0–1, measurable disease, and any IMDC risk group receive IV PF-08634404 as monotherapy or combined with one of two unspecified anticancer agents. PF-08634404/SSGJ-707 is an investigational bispecific antibody targeting PD-1 and VEGF, intended to combine checkpoint blockade with anti-angiogenic activity.

ClinicalTrials.gov ID: NCT07227415

AN INTERVENTIONAL OPEN-LABEL PHASE 1B/2 STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF PF-08634404 AS MONOTHERAPY AND COMBINATION THERAPY IN ADULT PARTICIPANTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic HCC, Child-Pugh A, ECOG 0–1, and no prior systemic therapy receive PF-08634404/SSGJ-707, an IV bispecific antibody targeting PD-1 and VEGF, either alone or with ipilimumab. The study evaluates dose/safety and preliminary efficacy of PF-08634404 plus CTLA-4 blockade versus PF-08634404 monotherapy in the first-line setting.

ClinicalTrials.gov ID: NCT07227012

ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously untreated locally advanced or unresectable HCC, measurable disease, and ECOG 0–1 receive pumitamig/BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, alone or with ipilimumab. A comparator cohort receives atezolizumab plus bevacizumab.

ClinicalTrials.gov ID: NCT07291076

A Phase 1a/1b Basket Trial of BMS-986504 With Standard-of-Care Therapy For Patients With Select Metastatic MTAP-deleted Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic or unresectable MTAP-deleted diffuse pleural mesothelioma, HER2-negative/PD-L1 CPS ≥1 gastroesophageal carcinoma, or previously treated urothelial carcinoma receive oral BMS-986504, an MTA-cooperative PRMT5 inhibitor targeting MTAP-deleted tumors, combined with disease-specific standard therapy. Regimens are BMS-986504 plus ipilimumab/nivolumab for mesothelioma, plus FOLFOX/nivolumab for gastroesophageal cancer, or plus gemcitabine/cisplatin or carboplatin followed by BMS-986504 maintenance for urothelial cancer.

ClinicalTrials.gov ID: NCT07532902

A 2-part Phase 1/2 Open-label Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ODM-212 in Combination With Anti-cancer Therapy in Participants With Advanced Solid Tumours

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1 and advanced/metastatic unresectable solid tumors in selected cohorts: mesothelioma, metastatic pancreatic ductal adenocarcinoma, or KRAS G12C-mutated NSCLC. All receive investigational oral ODM-212, a pan-TEAD/Hippo pathway inhibitor targeting YAP/TAZ–TEAD signaling, combined respectively with ipilimumab/nivolumab, gemcitabine/nab-paclitaxel, or sotorasib.

ClinicalTrials.gov ID: NCT07563738

AN INTERVENTIONAL OPEN-LABEL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF PF-08634404 IN COMBINATION WITH DIFFERENT ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Open-label study for adults with previously untreated locally advanced unresectable or metastatic squamous or nonsquamous NSCLC without actionable driver alterations, ECOG 0–1, measurable disease, and available PD-L1 status; Part B requires PD-L1 TPS ≥1%. Patients receive IV PF-08634404, an investigational bispecific PD-1/VEGF antibody, in combination with another anticancer agent, including sigvotatug vedotin, an integrin β6–directed MMAE antibody-drug conjugate, in one cohort.

ClinicalTrials.gov ID: NCT07227298